Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03641755 · ClinicalTrials.gov registry record · Phase 1

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

A Phase 1 study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 1
Development phase
10
Enrollment target
2
Study locations

NCT03641755 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03641755, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
2
Study locations

Study Summary

This research study is studying a combination of drugs as a possible treatment for breast cancer with a BRCA mutation. The interventions involved in this study are: * Sapacitabine (CYC682) * Olaparib (Lynparza™)

Conditions Studied

Breast Cancer

Interventions

  • DRUG Olaparib
  • DRUG Sapacitabine

Study Locations (2)

Massachusetts

  • Dana Farber Cancer Institute - Boston
  • Broad Institute of MIT - Cambridge

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2018-10-01
Est. Completion 2026-10-22
Phase Phase 1

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03641755

The ClinicalTrials.gov registry entry for NCT03641755 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.

NCT03641755 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03641755 about?

NCT03641755 is a clinical study titled "Olaparib + Sapacitabine in BRCA Mutant Breast Cancer". This research study is studying a combination of drugs as a possible treatment for breast cancer with a BRCA mutation. The interventions involved in this study are: * Sapacitabine (CYC682) * Olaparib (Lynparza™)

What is the current status of trial NCT03641755?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2018-10-01. Estimated completion is 2026-10-22.

What conditions does trial NCT03641755 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03641755?

The interventions under investigation include: Olaparib (DRUG), Sapacitabine (DRUG).

Who is sponsoring clinical trial NCT03641755?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03641755 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.